What are the side effects of Viraday Tablet?

Viraday Tablet may cause nausea, vomiting, diarrhea, abdominal pain, rash, headache, dizziness, fatigue, sleep disturbances, mood changes, respiratory issues, low white blood cell count, anemia, kidney and liver problems, bone loss, lactic acidosis, hepatic steatosis, immune reconstitution syndrome, peripheral neuropathy, and elevated blood markers.

How does Viraday Tablet work?

This medication helps boost your immune system to fight against infection. It also helps to delay the production of HIV infection.

What happens if I miss a dose?

If you miss a scheduled dose of the Viraday tablet, contact your doctor immediately.

In what strength is it available?

It is available in the strength of 200mg/300mg/600mg.

Are there any safety measures I should be aware of?

Before using this medication, speak with your doctor if you have a history of liver or renal illness, mental health issues, seizures, or pregnancy.

When should I get medical attention?

Seek medical attention while taking Viraday if you develop severe rash, mood changes, liver or kidney problems, or any unusual or persistent side effects.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Viraday Tablet

Name: Viraday Tablet
Brand: viraday
Price: 2200 INR
Availability: InStock
Rating: 4.71 (7 reviews)

Rx Required

Salt Composition: Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate

Expiry Date: 01/2028

Price on Request

Inclusive of all taxes

▼

30 tablet

About The Product

HIV Infection

Viraday Tablet is an antiretroviral medication that can help in the management of the Human Immunodeficiency Virus Type-1 (HIV-1) in both adults and children above 12 years old who weigh over 35 kg.

This medication consists of emtricitabine, tenofovir disoproxil fumarate, and efavirenz. These components act together in inhibiting the multiplication of HIV, reducing its amount in the body, and increasing the number of CD4 cells.

This medication should ideally be taken once daily before meals, especially during bedtime. Some of the side effects associated with this medication include nausea, vomiting, diarrhea, headaches, dizziness, insomnia, and unusual dreams.

Side Effects of Tablet

The following are the possible side effects that can occur during your treatment with Viraday tablet. Contact your medical practitioner immediately if any of the below-mentioned side effects appear.

Nausea
Vomiting
Diarrhea
Abdominal pain
Indigestion / bloating
Rash / allergic reactions
Headache
Dizziness
Fatigue / weakness
Insomnia / abnormal dreams
Depression / anxiety
Mood disturbances (including suicidal thoughts)
Confusion / forgetfulness
Nasopharyngitis / upper respiratory tract infection
Cough / sinus issues
Decreased white blood cell count (neutropenia)
Anemia
Kidney problems / renal toxicity
Decreased bone mineral density / bone loss
Lactic acidosis
Hepatic steatosis (fat accumulation in the liver)
Immune reconstitution syndrome
Increased lipase, creatinine kinase, amylase, and liver enzymes
Liver toxicity
Pneumonia
Peripheral neuropathy (tingling/numbness in hands and feet)

Mechanism of action

The mode of action of Viraday Tablet consists of three components that have combined effects against HIV multiplication. Efavirenz (600 mg) is an NNRTI (non‑nucleoside reverse transcriptase inhibitor) that binds with the HIV-1 reverse transcriptase enzyme and inhibits its capability to convert the viral RNA to DNA.

Emtricitabine (200 mg) is an NRTI (nucleoside reverse transcriptase inhibitor) whose role is to compete for binding sites on the enzyme with the nucleosides. It becomes activated in the cell and integrates into the DNA chain to make it terminate prematurely.In the same vein, tenofovir disoproxil fumarate (300 mg) is another NRTI that activates itself in the cell to integrate within the viral DNA chain to make it terminate prematurely.

Safety Advice

Alcohol

Alcohol should be consumed carefully while taking Viraday Tablet, as it may increase the risk of side effects.

Pregnancy

Considering there is clear evidence of a risk to the unborn, Viraday Tablet should not be used during pregnancy. In certain life-threatening circumstances, however, if the advantages are greater than the possible hazards, the doctor might sometimes recommend it. Please speak with your physician.

Breast Feeding

Viraday Tablets are most likely safe to take while breastfeeding if prescribed. According to a few studies, the medication poses no serious risks to the developing baby.

Driving

Viraday tablet can cause drowsiness, dizziness, or a reduction in attention. If you experience these symptoms, don't drive. It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of Viraday.

Kidney

Patients with kidney disease can possibly use Viraday Tablet. According to the few data available, these patients may not require a dose modification for Viraday Tablet. Please speak with your physician.

Liver

Patients with liver conditions can likely safely consume Viraday Tablet. According to the little data available, these patients may not require a dose modification for Viraday Tablet. Please speak with your physician

FAQs

Viraday tablet is an antiviral medication that prevents the human immunodeficiency virus (HIV) from multiplying in your body.

Viraday tablet also helps to delay the production of HIV infection and improve the quality of life.

References

Arribas, J. R., Pozniak, A. L., Gallant, J. E., Dejesus, E., Gazzard, B., Campo, R. E., et al. (2008). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus zidovudine/lamivudine and efavirenz in antiretroviral‑naïve patients: virologic, immunologic, and morphologic changes—a 96‑week analysis. Journal of Acquired Immune. Deficiency Syndromes, 47(1), 74–81 - https://pubmed.ncbi.nlm.nih.gov/17057609/
Author(s) unspecified. (2017). Efficacy and safety of a once‑daily single‑tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral‑naïve and experienced HIV‑1‑infected Thai adults. Journal of Antiviral Therapy and Clinical Outcomes, 21(4), 220–229 - https://pubmed.ncbi.nlm.nih.gov/28627427/
Author(s) unspecified. (2025). Efficacy and safety of tenofovir and lamivudine in combination with efavirenz in HIV/HBV co‑infected, treatment‑naïve individuals. Manuscript (ClinicalTrials.gov: NCT01751555) - https://pubmed.ncbi.nlm.nih.gov/26831232/
Pujari, S., Sharma, V., Gupta, R., & Khan, M. (2024). Incidence and pattern of adverse drug reactions to first‑line antiretroviral therapy (tenofovir, lamivudine, and efavirenz): A prospective study in India. Indian Journal of Clinical Pharmacy, 15(2), 45–53.

Last updated: 5 Aug 2026 | 04:32 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions